A groundbreaking study shows that liquid biopsy can significantly speed up the diagnosis of Epstein-Barr virus (EBV)-positive Burkitt’s lymphoma in sub-Saharan Africa. This highly aggressive cancer, primarily affecting children, requires rapid diagnosis for timely treatment, but limited pathology infrastructure often causes delays.
Researchers analyzed 377 patients with suspected lymphoma across four hospitals in Tanzania and Uganda. Using circulating tumor DNA markers, they developed predictive models for diagnosis. The best model achieved an area under the curve of 0.95, with 86% sensitivity and 95% specificity.
Liquid biopsy was the only diagnostic result available in 42% of cases, reducing the median turnaround time from 46.8 days to 6.5 days. This approach could transform diagnostic pathways in endemic regions, helping clinicians make earlier decisions and improve patient outcomes.
Future work will focus on scaling this approach and evaluating its impact on survival outcomes in real-world settings.